Synektik
Radiopharmaceuticals + robotics · Oncology / cardiology imaging
Overview
Manufactures PET radiopharmaceuticals and distributes da Vinci surgical robots across Central Europe; developing a cardiac-perfusion PET tracer.
What they do
Synektik S.A. is a Warsaw-Stock-Exchange-listed medical-technology group operating two main businesses: production of PET radiopharmaceuticals for oncology and cardiology imaging, and distribution of Intuitive Surgical's da Vinci surgical robots across Poland and Central Europe (including the Czech Republic, Slovakia and the Baltics). The company also provides imaging equipment and service. Its robotic-surgery distribution has become a major revenue driver alongside the higher-margin radiopharmaceuticals segment.
Lead program & status
Synektik's R&D lead is a proprietary cardiac-perfusion PET radiotracer ("kardioznacznik") for myocardial perfusion imaging, which the company has worked to advance through clinical development and signaled it would spin off as part of its R&D activities. Commercially, Synektik reported strong recent results: in fiscal year 2024/2025 it sold/installed 27 da Vinci systems (9 in Q4 alone), with Q3 FY2024/25 revenue around PLN 154 million and record quarterly profits, and guided toward 30+ robot placements including first deliveries to the Baltic countries. Radiopharmaceutical sales also grew sharply year-on-year.
Why it matters
Synektik blends a cash-generative robotics-distribution franchise with proprietary radiotracer development. A successful cardiac PET tracer would give it an owned product in a growing molecular-imaging niche, diversifying beyond distribution.
FAQ
- What are Synektik's two main businesses?
- Manufacturing PET radiopharmaceuticals for oncology and cardiology imaging, and distributing da Vinci surgical robots across Central Europe.
- What is Synektik's lead R&D program?
- A proprietary cardiac-perfusion PET radiotracer for myocardial perfusion imaging, which the company has worked to advance and planned to spin off.
- How is Synektik performing financially?
- It reported record results in FY2024/2025, including 27 da Vinci systems sold/installed and roughly PLN 154 million revenue in Q3 FY2024/25.
Technology
Synektik works in Radioligand Therapy (RLT) — A targeting molecule that delivers a radioactive payload to kill tumors from within.
Read the Radioligand Therapy (RLT) brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.